Licensing And PartnershipsThe company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders is seen as a positive development.

New Treatment DevelopmentsSimufilam advancement as a treatment for seizures would be a positive development.

Bears Say

Clinical Trial ResultsResults from the 76-week ReFocus-ALZ Phase 3 trial with simufilam in patients with mild-to-moderate Alzheimer’s disease did not meet the study’s pre-specified endpoints.

Clinical Trial TerminationTop-line results from ReThink-ALZ, a 52-week, 804-patient, double-blind Phase 3 clinical trial with simufilam in patients with mild-to-moderate Alzheimer's disease, did not meet the study’s pre-specified co-primary, secondary, and exploratory biomarker endpoints, leading to the trial's termination.

Stock PerformanceAlthough the stock currently trades near its 52-week low of $2.40 a share, until there is insight into simufilam’s prospects, the analyst remains on the sidelines.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

5.23% Insiders

7.21% Mutual Funds

0.15% Other Institutional Investors

81.83% Public Companies and

Individual Investors

Detailed Ownership Overview >

SAVA FAQ

What was Cassava Sciences’s price range in the past 12 months?

Cassava Sciences lowest stock price was $1.15 and its highest was $42.20 in the past 12 months.

What is Cassava Sciences’s market cap?

Cassava Sciences’s market cap is $121.74M.

When is Cassava Sciences’s upcoming earnings report date?

Cassava Sciences’s upcoming earnings report date is Jul 30, 2025 which is in 4 days.

How were Cassava Sciences’s earnings last quarter?

Cassava Sciences released its earnings results on May 08, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.48.

Is Cassava Sciences overvalued?

According to Wall Street analysts Cassava Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cassava Sciences pay dividends?

Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here

What is Cassava Sciences’s EPS estimate?

Cassava Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cassava Sciences have?

Cassava Sciences has 48,307,896 shares outstanding.

What happened to Cassava Sciences’s price movement after its last earnings report?

Cassava Sciences reported an EPS of -$0.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.974%.

Which hedge fund is a major shareholder of Cassava Sciences?

Currently, no hedge funds are holding shares in SAVA

Cassava Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-70.59%

Trailing 12-Months

Asset Growth

-9.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.